Aura Biosciences falls 2.24% in Thursday's session
Aura Biosciences (AURA) shares declined by 2.24% to 6.98 USD in the United States health care sector on November 19, 2026. This drop occurred on a Thursday, with the stock closing below its previous day's close of 7.14 USD. The article highlights that the reported price is the last traded price, not the exchange's official closing price, and is part of an automated market data report.
Discipline and Rules-Based Execution in AURA Response
This report provides a detailed analysis of Aura Biosciences Inc. (NASDAQ: AURA), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles with specific entry, target, and stop loss levels. The analysis also includes multi-timeframe signal analysis, identifying strong biases in the mid and long-term horizons.
OXB partners with Aura Biosciences for phase 3 drug manufacturing By Investing.com
OXB has announced a manufacturing and supply partnership with Aura Biosciences Inc. to support the late-stage development and manufacturing of belzupacap sarotalocan, a drug candidate for ocular cancers. OXB will conduct manufacturing activities from its FDA-approved facilities in Bedford, Massachusetts, and Durham, North Carolina. This collaboration supports Aura's Phase 3 clinical program and prepares for potential commercial supply, marking OXB's entry into virus-like drug conjugate manufacturing.
OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
OXB (LSE: OXB) has confirmed its manufacturing and supply partnership with Aura Biosciences (NASDAQ: AURA), supporting the late-stage development and future commercial supply of Aura's lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar). This collaboration leverages OXB's extensive experience in process characterisation, PPQ, and commercial-scale manufacturing from its FDA-approved facility in Durham, North Carolina. The partnership represents OXB's entry into virus-like drug conjugate (VDC) manufacturing, an adjacent segment to its core viral vector expertise, further strengthening its position in the cell and gene therapy CDMO space.
Private funds hold over 5% of Aura Biosciences (AURA), with their manager reporting shared voting power.
ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger, have reported a 5.2% passive stake in Aura Biosciences (AURA) through private investment funds they manage. They hold shared voting and dispositive power over 5,385,879 common shares. This filing is based on 103,950,771 shares outstanding as of September 30, 2026.
Aura Biosciences (AURA) medical chief's automatic share sales cover stock-vesting taxes.
Janet Jill Hopkins, Chief Medical Officer at Aura Biosciences, sold 16,903 common shares at a weighted average price of $7.05 per share on November 16, 2026. These sales were automatic and nondiscretionary, executed solely to cover tax withholding obligations associated with the vesting of her restricted stock units. Following the transaction, Hopkins directly holds 363,287 shares of Aura Biosciences.
Form 4 Aura Biosciences Inc: Janet Jill Hopkins (Chief Medical Officer) For: 16 November
This article reports on a Form 4 filing for Aura Biosciences Inc, specifically regarding Chief Medical Officer Janet Jill Hopkins, with the transaction date listed as November 16. Form 4 filings are regulatory documents disclosing changes in beneficial ownership of securities by company insiders. The brief piece indicates that Aura Biosciences Inc. (AURA) saw a modest price increase of 1.55%.
Form 4 Aura Biosciences Inc: Janet Jill Hopkins (Chief Medical Officer) For: 16 November
This article reports on a Form 4 filing for Aura Biosciences Inc, specifically concerning Chief Medical Officer Janet Jill Hopkins for November 16. Form 4 filings detail changes in beneficial ownership of company stock by insiders. The article also provides the stock performance of Aura Biosciences Inc (AURA).
Aura Biosciences, Inc. (AURA) Stock Price, News, Quote & History
Aura Biosciences, Inc. (AURA) is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with its lead candidate bel-sar in late-stage clinical development for choroidal melanoma and early-stage trials for bladder cancer. The article provides a detailed financial overview including stock performance, key metrics, earnings trends, analyst ratings, and valuation measures. As of the article's data, AURA's stock was trading at $7.11, showing significant year-to-date and 1-year returns, though it had negative 5-year performance.
Aura Biosciences Insiders Made A Wise Decision By Selling US$876k Worth Of Stock
Aura Biosciences, Inc. (NASDAQ:AURA) saw insiders sell US$876k worth of stock over the last year, with the largest single transaction being US$241k by Elisabet de los Pinos at a price below the current market value. While the stock has recently risen by 14%, the insider selling suggests a potential expected downturn, as no insiders bought shares in the past year. Insider ownership remains relatively low at 1.2% of the company, indicating that major shareholders should monitor insider activity and other risks before investing.
How Aura Biosciences Inc. (AURA) Affects Rotational Strategy Timing
Aura Biosciences Inc. (NASDAQ: AURA) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop levels. The stock exhibits an exceptional 58.5:1 risk-reward setup, targeting a 16.1% gain versus 0.3% risk.
Aura Biosciences, Inc. (AURA) Tops Q3 EPS by 8c
Aura Biosciences, Inc. (NASDAQ: AURA) announced its Q3 earnings, reporting an EPS of ($0.29). This figure was $0.08 better than the analyst consensus estimate of ($0.37). The stock price for AURA was $7.66, reflecting a 16.77% increase on the day.
Form 8K Aura Biosciences Inc For: 9 November By Investing.com
This article announces that Aura Biosciences Inc. has filed a Form 8K on November 9, 2026. The filing is available through Investing.com, a financial markets platform. The document is likely to contain significant corporate events that investors should be aware of.
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences (NASDAQ: AURA) announced its third-quarter 2026 financial results, highlighting that its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma is on track for topline data in the second half of 2027, with all treatment visits completed. The company also established a new manufacturing relationship to secure designated capacity for bel-sar and reported a cash runway extending into the first half of 2029. Additionally, Aura Biosciences will host an investor and analyst virtual event in December 2026 to discuss early choroidal melanoma.
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences (NASDAQ: AURA) reported a widened net loss of $32.066 million for Q3 2026, up from $26.130 million a year prior, though loss per share narrowed to $0.29. The company completed treatment for all 108 participants in its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in H2 2027. Aura anticipates its $297.2 million in cash and marketable securities will fund operations into the first half of 2029.
AURA: SEC Form 10-Q filed by Aura Biosciences Inc.
Aura Biosciences Inc. filed its quarterly report (Form 10-Q) for Q3 2026, revealing 104.1 million common shares outstanding as of November 4, 2026. The filing details a May 2026 follow-on offering that raised $280.8 million in net proceeds at $6.00 per share, which diluted existing shareholders but added cash to the balance sheet.
Aura Biosciences Reports 104 Million Shares Outstanding and Phase 3 Trial Update in Q3 2026 Filing
Aura Biosciences filed its Q3 2026 Form 10-Q, reporting 104,074,302 shares outstanding as of November 4, 2026. The company also announced the completion of enrollment for its pivotal Phase 3 clinical trial for bel-sar, its sole drug candidate, with topline data expected in late 2027. The filing highlighted the company's reliance on bel-sar, its history of net losses, and various operational and regulatory risks.
Aura Biosciences CEO to present at Stifel 2026 Healthcare Conference on novel ocular cancer therapy
Aura Biosciences announced that its CEO, Natalie Holles, will present at the Stifel 2026 Healthcare Conference on November 10, 2026, to discuss their innovative ocular cancer therapy, Bel-sar. Bel-sar is a first-in-class treatment aimed at preserving vision while targeting ocular tumors, with a Phase 3 study for early choroidal melanoma fully enrolled and ongoing research into other ocular cancers. The presentation will highlight Aura's advancements and dedication to improving patient outcomes.
Aura Biosciences CEO to Speak at Stifel Conference Nov. 10 | AURA Stock News
Aura Biosciences (NASDAQ: AURA) announced that its CEO and President, Natalie Holles, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. ET. A live webcast and subsequent replay will be available on the company's Investors & Media page. The company is a clinical-stage biotechnology firm developing bel-sar, a therapy for ocular cancers.
Aura Biosciences, Inc. (AURA) Seasonal returns chart
This article from Yahoo Finance presents the historical seasonality chart for Aura Biosciences, Inc. (AURA). It displays the average monthly price return for the company's stock, covering a period from 2021 to 2026, and includes various timeframes for analysis. The page also provides current stock performance data for AURA.
Aura Biosciences, Inc. (AURA) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for Aura Biosciences, Inc. (AURA), showing the average monthly price return between 2021 and 2026. The stock's current price is provided, along with its performance at close and after hours.
Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027
Aura Biosciences is presented as a low-risk, fully funded company with $323.8 million in cash, expected to support operations through the first half of 2029. The company is focused on bel-sar treatment for early choroidal melanoma, with pivotal Phase 3 trial data anticipated in 2027. Despite trading near its cash value, its late-stage asset and strong trial design suggest market undervaluation.
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones
This article provides a detailed analysis of Aura Biosciences Inc. (AURA) from a quantitative research perspective, identifying neutral near and mid-term readings but a long-term positive bias. It highlights elevated downside risk due to a lack of additional long-term support and offers three AI-generated institutional trading strategies: Position Trading (Long), Momentum Breakout (Breakout), and Risk Hedging (Short), along with multi-timeframe signal analysis.
AURA Q3'26 Earnings: revenue estimate is 0 USD
Aura Biosciences, Inc. (AURA) is scheduled to release its Q3'26 earnings on November 5, with an estimated revenue of 0 USD and an anticipated EPS of (0.37) USD. The article provides a table detailing historical and estimated revenue and EPS figures, including EPS surprises.
Aura Biosciences Share News - Latest Updates, Live News & More
Aura Biosciences (AURA) stock performance shows a recent decline, with a 2.69% drop in 1 day and 2.57% in 1 month, although it is up 9.13% over the last year. Upcoming news includes the Q3FY26 earnings call scheduled for November 12, 2026, following the release of financial results and an Appendix 4C and Quarterly Activities Report due October 30, 2026. Earlier news indicates that the CEO spoke at a Morgan Stanley conference in September and the company granted equity awards to new executives.
Aura Biosciences, Inc. Estimates – NASDAQ:AURA
This page provides financial actuals and estimates for Aura Biosciences, Inc. (NASDAQ:AURA), allowing users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time for informed decision-making. The platform offers detailed views of income statements, balance sheets, and cash flow, both annually and quarterly.
Three entities report a passive stake above 5% in Aura Biosciences (AURA).
A Schedule 13G SEC filing reveals that ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. collectively hold a passive stake of approximately 5.1% in Aura Biosciences (AURA). This represents 5,248,841 shares of common stock based on 103,704,809 shares outstanding as of August 6, 2026. The entities, all organized under the laws of the Netherlands, disclaim membership in a formal "group" despite making a joint filing.
Forbion Entities Reveal 5.1% Stake in Aura Biosciences via SEC Filing
Three Forbion entities, including ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V., have disclosed a collective beneficial ownership of 5,248,841 shares in Aura Biosciences, representing approximately 5.1% of the company's outstanding common stock. This disclosure was made through a Schedule 13G filing with the SEC on October 1, 2026, stemming from an event on September 25, 2026. The entities are based in the Netherlands and collectively hold shared voting and dispositive power over these shares, clarifying that their intent is not to change or influence company control.
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones
This article provides a detailed analysis of Aura Biosciences Inc. (AURA) stock, highlighting weak near and mid-term sentiment but a strong long-term outlook. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis emphasizes risk management and leverages AI-generated signals across multiple timeframes.
Aura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry Index
Aura Biosciences, Inc. (NasdaqGM:AURA) has been added to the S&P Biotechnology Select Industry Index. The company is a clinical-stage biotechnology firm developing precision therapies for solid tumors, with its lead candidate, bel-sar, in late-stage development for choroidal melanoma. This inclusion highlights the company's progress and recognition within the biotechnology sector.
Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage
Aura Biosciences presented its investigational eye cancer therapy, bel-sar, at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its potential to transform treatment for early choroidal melanoma by preserving vision while controlling tumors. The company is focusing on ocular oncology, with Phase III data for bel-sar expected in the second half of 2026. Aura believes bel-sar addresses a significant unmet medical need and targets a large, underserved market, despite the inherent risks of late-stage biotech development.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards to three new executives: Erica Kratz (Chief Regulatory and Quality Officer), Susan Abu-Absi (Chief Operating Officer), and Julie Person (Chief People Officer). These awards, granted on September 1, 2026, include non-qualified stock options and restricted stock units (RSUs), approved under Nasdaq Listing Rule 5635(c)(4). The grants are part of the company's compensation strategy and are subject to vesting schedules tied to continued service.
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences, a clinical-stage biotechnology company, announced that its CEO and President, Natalie Holles, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. She will present during a fireside chat at 2:35 p.m. ET, which will be webcast live. The company is developing bel-sar, a first-in-class therapy for ocular cancers.
Aura Biosciences CEO to speak at Morgan Stanley healthcare conference
Aura Biosciences announced that its CEO and President, Natalie Holles, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 2:35 pm ET. The company is a clinical-stage biotechnology firm developing bel-sar, a first-in-class therapy for ocular cancers, with its Phase 3 study for early choroidal melanoma fully enrolled. A live webcast of the event will be available on the company's investor relations website.
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The company is a clinical-stage biotechnology firm developing bel-sar, a therapy for ocular cancers, with a Phase 3 study for early choroidal melanoma fully enrolled. A live webcast of the fireside chat will be available on the company's website.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards to three new executives: Erica Kratz (Chief Regulatory and Quality Officer), Susan Abu-Absi (Chief Operating Officer), and Julie Person (Chief People Officer). These awards, granted on September 1, 2026, consist of non-qualified stock options and restricted stock units, approved in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are designed to attract and retain key talent in the clinical-stage biotechnology company focused on ocular cancer therapies.
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16
Aura Biosciences (NASDAQ: AURA) announced that its CEO and President, Natalie Holles, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 2:35 p.m. ET. A live webcast and a 90-day replay of the chat will be available on the company's website. Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a therapy for ocular cancers.
COO at Aura Biosciences (AURA) lands new option and RSU package
Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi received an inducement award consisting of 265,487 stock options with an exercise price of $7.43 per share and 134,513 Restricted Stock Units (RSUs). The RSUs will vest in four annual installments starting September 15, 2027, while the stock options vest 25% on August 10, 2027, with the remainder vesting monthly over 36 installments, both subject to continued service. This equity package aims to align the COO's interests with the company's long-term performance.
Aura Biosciences grants equity inducement awards to three new executives
Aura Biosciences (NASDAQ: AURA) has granted inducement equity awards to three new executives: Erica Kratz, Susan Abu-Absi, and Julie Person. These awards, consisting of non-qualified stock options and restricted stock units, were approved under Nasdaq Listing Rule 5635(c)(4). The equity package, with an option exercise price of $7.43 per share, is structured with long-term vesting schedules over four years to align executive incentives with the company's clinical-stage development milestones.
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives
Aura Biosciences has granted inducement equity awards to its new Chief Regulatory and Quality Officer, Chief Operating Officer, and Chief People Officer on September 1, 2026. These awards, consisting of non-qualified stock options and restricted stock units, were approved by the Compensation Committee in accordance with Nasdaq rules. The company, which is developing bel-sar for ocular cancers, aims to incentivize its new executive team with these equity grants.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences, Inc. announced inducement equity awards to its new Chief Regulatory and Quality Officer, Chief Operating Officer, and Chief People Officer on September 1, 2026. These awards, approved by the Compensation Committee, include non-qualified stock options and restricted stock units (RSUs) with specific vesting schedules. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026)
Aura Biosciences, Inc. filed an EFFECT SEC filing which was accepted on August 21, 2026, for Form S-3 with an effectiveness date of August 20, 2026. The filing has a neutral impact and sentiment according to AI-generated analysis. The company's stock, AURA, has a market cap of $805.79 million and is ranked among top gainers in various timeframes.
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell
Wall Street Zen has downgraded Aura Biosciences (NASDAQ:AURA) from "hold" to "sell" amidst mixed analyst coverage and the company's recent financial performance. Aura Biosciences reported a quarterly loss of $0.48 per share, missing consensus estimates, and has cut 20% of its workforce to preserve cash for its late-stage eye-cancer trial. The stock's price performance reflects these concerns, though institutional investors hold a significant stake.
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap
A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The report also highlights that prefunded warrants held by these funds are subject to a 9.99% beneficial ownership limitation to prevent exceeding this threshold upon exercise.
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership
Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. The filing indicates that no single client of Long Focus Capital Management, LLC owns more than 5% of Aura Biosciences' class of securities.
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)
This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for Corbus Pharmaceuticals, anticipating a substantial increase from current levels.
HC Wainwright Raises Earnings Estimates for Aura Biosciences
HC Wainwright has increased its earnings estimates for Aura Biosciences (NASDAQ:AURA), projecting a smaller loss for Q3 2026 and forecasting positive EPS by 2030. Despite maintaining a "Buy" rating, the firm lowered its price target to $18, reflecting a more cautious valuation. Aura Biosciences reported a larger-than-expected quarterly loss of -$0.48, missing consensus estimates.
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift
H.C. Wainwright has lowered its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24, while maintaining a Buy rating. This adjustment comes as Aura Biosciences shifts its strategic focus and capital allocation towards ocular oncology programs, particularly after completing enrollment for its Phase 3 CoMpass trial. The company is also scaling back investment in its non-muscle invasive bladder cancer program, now modeling it for a potential out-licensing scenario.
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person
Aura Biosciences, Inc. (AURA) has filed a Form 3, an initial statement of beneficial ownership, for its new Chief People Officer, Julie Person. This filing registers her status as an officer of the company, but it indicates no transactions or current holdings of company securities by her at this time. The document confirms her role and obligations for future reporting of beneficial ownership.
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3
Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing establishes her insider status for future reporting but does not report any stock transactions or derivative positions at this time. The document confirms her role as COO and indicates she is not a 10% owner.